selegiline has been researched along with memantine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Camins, A; Camps, P; Duque, MD; Kelly, JM; López-Querol, M; Prathalingam, SR; Sureda, FX; Torres, E; Valverde, E; Vázquez, S | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Adolph, O; Appenroth, D; Enzensperger, C; Fleck, C; Föhr, KJ; Gaube, F; Lehmann, J; Otto, R; Penzis, R; Robaa, D; Warncke, P; Winckler, T | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Danysz, W; Quack, G; Rogoz, Z; Skuza, G | 1 |
| Gavrilova, SI; Zharikov, GA | 1 |
| Arya, P; Butler, R; Warner, J | 1 |
| Butler, R; Warner, J; Wuntakal, B | 1 |
| Tariot, PN | 1 |
| Feldman, HH; Hsiung, GY | 1 |
| Büttner, T; Csoti, I; Kassubek, J; Reichmann, H; Riederer, P; Schulz, JB; Wüllner, U | 1 |
| Jordan-Sciutto, KL; Kolson, DL; Lindl, KA; Marks, DR | 1 |
8 review(s) available for selegiline and memantine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Estrogens; Ginkgo biloba; Humans; Indans; Memantine; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuronal Plasticity; Neuroprotective Agents; Neurotransmitter Agents; Nicergoline; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Piracetam; Pyrithioxin; Rivastigmine; Selegiline; Tacrine; Time Factors | 2001 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine | 2005 |
Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Transfer; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Selegiline; Severity of Illness Index; Treatment Outcome; Vitamin E | 2006 |
Pharmacological treatment in moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine; Selegiline; Severity of Illness Index; Vitamin E | 2008 |
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methylaspartate; Parkinson Disease; Piperidines; Selegiline | 2010 |
HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.
Topics: AIDS Dementia Complex; Animals; Anti-HIV Agents; Brain; HIV-1; Humans; Memantine; Minocycline; Neuroimmunomodulation; Selegiline | 2010 |
5 other study(ies) available for selegiline and memantine
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities.
Topics: Amines; Animals; Antiparkinson Agents; Cells, Cultured; Humans; Memantine; Molecular Structure; Neurons; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
Topics: Animals; Carbolines; Cholinesterase Inhibitors; Computational Biology; Excitatory Amino Acid Antagonists; Humans; Indicators and Reagents; Ligands; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship | 2015 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 1994 |